ACT up +3.67% percent Today $ACT High is at 254.67
Post# of 91
Posted On: 11/17/2014 10:34:48 AM
ACT up +3.67% percent Today $ACT High is at 254.67 and the Low 243.00 with current volume of 6,998,299.
Recent News posted below.
Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - 2 mins ago
Rigrodsky & Long, P.A.:
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51)
Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - 17 mins ago
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 213.00 (+14.35), VRX: 135.40 (+1.19), ACT: 253.20 (+9.43)
Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - 20 mins ago
ACT: 253.20 (+9.43), VRX: 135.40 (+1.19)
Stock Market Today: U.S. Stocks Slip After Japan's Recession Surprise
at The Street - 46 mins ago
News that Japan fell into recession again in the third quarter causes waves on global markets early Monday morning.
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51), HAL: 51.11 (-3.97), TSN: 42.26 (+1.60), JD: 25.87 (-1.14), BHI: 67.16 (+7.27), BABA: 114.75 (-0.35)
Valeant Comments On Allergan Announcement
PR Newswire - 1 hr 5 mins ago
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51), VRX: 135.40 (+1.19), VRX.TO: 153.25 (+1.78)
It's official: Actavis buys Allergan
Seeking Alpha - at Seeking Alpha - 1 hr 7 mins ago
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51)
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue
PR Newswire - 1 hr 19 mins ago
Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share. The combination will create one of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015. The transaction has been unanimously approved by the Boards of Directors of Actavis and Allergan, and is supported by the management teams of both companies. Actavis anticipates that the expected permanent financing structure, consisting of a combination of new equity and debt, will support an investment grade rating and provide long-term financing flexibility.
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51)
Stock Futures Set For Weak Open; Halliburton, Baker Hughes Merge
at Investor's Business Daily - 1 hr 22 mins ago
Stock futures pointed modestly lower ahead of Monday's open as merger news stirred some of the most notable premarket stock moves. Dow futures sifted 27.7 points below fair market value. Nasdaq 100 futures were 9.1 points lower, and S&P 500 futures...
AGN: 213.00 (+14.35), HAS: 56.14 (+2.12), VRX: 135.35 (+1.14), ACT: 253.28 (+9.51), HAL: 51.10 (-3.98), DIS: 90.73 (-0.07), DWA: 22.27 (-3.75), BHI: 67.20 (+7.31)
Today's Market: Pharma And Tech Companies In Focus This Morning
Matthew Smith - at Seeking Alpha - 1 hr 28 mins ago
AGN: 213.00 (+14.35), VRX: 135.35 (+1.14), ACT: 253.28 (+9.51), LNKD: 225.34 (-8.55), FB: 75.32 (+0.44), MSFT: 49.27 (-0.31), GOOG: 537.22 (-7.18)
Actavis Rumored to be Close to Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 34 mins ago
As per market rumors, Actavis (ACT) is closing in on a deal to acquire Allergan (AGN) for over $65.5 billion.
DRTX: 23.91 (+0.16), ZTS: 44.09 (+0.95), AGN: 213.00 (+14.35), ACT: 253.28 (+9.51), VRX: 135.35 (+1.14)
Stock Market Today: Japan’s Surprise Recession Weighs on U.S. Stock Futures
at The Street - 1 hr 54 mins ago
U.S. stock futures trade lower on Monday, weighed down by Japan's return into recession.
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51), HAL: 51.10 (-3.98), TSN: 42.26 (+1.60), JD: 25.87 (-1.14), BHI: 67.20 (+7.31), BABA: 114.79 (-0.31)
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
PR Newswire - 2 hrs 34 mins ago
Actavis plc (NYSE: ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata Therapeutics, Inc. (NASDAQ: DRTX), an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. As previously announced, Actavis offered to purchase all outstanding shares of Durata for $23.00 per share in cash, or approximately $675 million in the aggregate, and one contingent value right (CVR) per share, entitling the holder to receive additional cash payments of up to $5.00 per CVR if certain regulatory or commercial milestones related to Durata's lead product DALVANCETM are achieved.
DRTX: 23.91 (+0.16), ACT: 253.21 (+9.44)
Tracking Bill Ackman's Pershing Square Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - 2 hrs 54 mins ago
ZTS: 44.09 (+0.95), AGN: 213.00 (+14.35), HLF: 38.50 (unch), VRX: 135.35 (+1.14), ACT: 253.21 (+9.44), HHC: 142.99 (-0.69), PAH: 25.57 (+0.07), CP: 206.78 (+2.22), APD: 134.88 (+0.17), BKW: 32.30 (+0.01)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 135.35 (+1.14), ACT: 253.21 (+9.44), F: 15.44 (+0.30), FB: 75.32 (+0.44), PFE: 30.03 (-0.31), AGN: 213.00 (+14.35), YHOO: 51.44 (-0.31), PBR: 9.63 (-0.32), DFS: 64.80 (-0.18), DTSI: 32.96 (-0.07), SPY: 204.26 (+0.02), LNKD: 225.34 (-8.55), QQQ: 103.10 (-0.12), AME: 51.16 (-0.54), MRK: 59.86 (+0.79), AOL: 46.40 (+0.36), AZN: 71.97 (-0.88), GM: 32.10 (+0.31), CVEO: 10.62 (-0.02), DD: 70.65 (-0.15)
Actavis near deal to acquire Allergan for $210-220/share
Seeking Alpha - at Seeking Alpha - Sun Nov 16, 2:51PM CST
AGN: 213.00 (+14.35), ACT: 253.21 (+9.44), VRX: 135.35 (+1.14)
Eye Best Mutual Funds Like Magellan For Great Stocks
at Investor's Business Daily - Fri Nov 14, 4:50PM CST
Leery about picking stocks on your own? Novice traders with little knowledge or confidence to pick winning stocks may benefit by first seeing what great mutual funds are buying. Funds rule the market. After all, they spend millions, even billions, of...
KMX: 54.88 (-0.77), ACT: 253.21 (+9.44), APH: 50.74 (-0.12), JPM: 60.16 (-0.12), ALXN: 190.59 (+1.83), GOOGL: 548.25 (-6.94), BAC: 17.10 (-0.04), NXPI: 74.09 (+0.36), MSFT: 49.28 (-0.30), VZ: 51.31 (-0.19), AAPL: 114.75 (+0.57), UNP: 120.46 (-0.25)
Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.77 (+0.66), BIIB: 307.93 (+2.50), JNJ: 108.64 (+0.48), ACT: 253.21 (+9.44)
Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST
ZTS: 44.09 (+0.95), AGN: 213.00 (+14.35), VRX: 135.35 (+1.14), ACT: 253.21 (+9.44)
Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 44.09 (+0.95), AGN: 213.00 (+14.35), ACT: 253.21 (+9.44), VRX: 135.35 (+1.14)
Recent News posted below.
Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - 2 mins ago
Rigrodsky & Long, P.A.:
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51)
Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - 17 mins ago
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 213.00 (+14.35), VRX: 135.40 (+1.19), ACT: 253.20 (+9.43)
Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - 20 mins ago
ACT: 253.20 (+9.43), VRX: 135.40 (+1.19)
Stock Market Today: U.S. Stocks Slip After Japan's Recession Surprise
at The Street - 46 mins ago
News that Japan fell into recession again in the third quarter causes waves on global markets early Monday morning.
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51), HAL: 51.11 (-3.97), TSN: 42.26 (+1.60), JD: 25.87 (-1.14), BHI: 67.16 (+7.27), BABA: 114.75 (-0.35)
Valeant Comments On Allergan Announcement
PR Newswire - 1 hr 5 mins ago
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51), VRX: 135.40 (+1.19), VRX.TO: 153.25 (+1.78)
It's official: Actavis buys Allergan
Seeking Alpha - at Seeking Alpha - 1 hr 7 mins ago
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51)
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue
PR Newswire - 1 hr 19 mins ago
Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share. The combination will create one of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015. The transaction has been unanimously approved by the Boards of Directors of Actavis and Allergan, and is supported by the management teams of both companies. Actavis anticipates that the expected permanent financing structure, consisting of a combination of new equity and debt, will support an investment grade rating and provide long-term financing flexibility.
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51)
Stock Futures Set For Weak Open; Halliburton, Baker Hughes Merge
at Investor's Business Daily - 1 hr 22 mins ago
Stock futures pointed modestly lower ahead of Monday's open as merger news stirred some of the most notable premarket stock moves. Dow futures sifted 27.7 points below fair market value. Nasdaq 100 futures were 9.1 points lower, and S&P 500 futures...
AGN: 213.00 (+14.35), HAS: 56.14 (+2.12), VRX: 135.35 (+1.14), ACT: 253.28 (+9.51), HAL: 51.10 (-3.98), DIS: 90.73 (-0.07), DWA: 22.27 (-3.75), BHI: 67.20 (+7.31)
Today's Market: Pharma And Tech Companies In Focus This Morning
Matthew Smith - at Seeking Alpha - 1 hr 28 mins ago
AGN: 213.00 (+14.35), VRX: 135.35 (+1.14), ACT: 253.28 (+9.51), LNKD: 225.34 (-8.55), FB: 75.32 (+0.44), MSFT: 49.27 (-0.31), GOOG: 537.22 (-7.18)
Actavis Rumored to be Close to Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 34 mins ago
As per market rumors, Actavis (ACT) is closing in on a deal to acquire Allergan (AGN) for over $65.5 billion.
DRTX: 23.91 (+0.16), ZTS: 44.09 (+0.95), AGN: 213.00 (+14.35), ACT: 253.28 (+9.51), VRX: 135.35 (+1.14)
Stock Market Today: Japan’s Surprise Recession Weighs on U.S. Stock Futures
at The Street - 1 hr 54 mins ago
U.S. stock futures trade lower on Monday, weighed down by Japan's return into recession.
AGN: 213.00 (+14.35), ACT: 253.28 (+9.51), HAL: 51.10 (-3.98), TSN: 42.26 (+1.60), JD: 25.87 (-1.14), BHI: 67.20 (+7.31), BABA: 114.79 (-0.31)
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
PR Newswire - 2 hrs 34 mins ago
Actavis plc (NYSE: ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata Therapeutics, Inc. (NASDAQ: DRTX), an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. As previously announced, Actavis offered to purchase all outstanding shares of Durata for $23.00 per share in cash, or approximately $675 million in the aggregate, and one contingent value right (CVR) per share, entitling the holder to receive additional cash payments of up to $5.00 per CVR if certain regulatory or commercial milestones related to Durata's lead product DALVANCETM are achieved.
DRTX: 23.91 (+0.16), ACT: 253.21 (+9.44)
Tracking Bill Ackman's Pershing Square Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - 2 hrs 54 mins ago
ZTS: 44.09 (+0.95), AGN: 213.00 (+14.35), HLF: 38.50 (unch), VRX: 135.35 (+1.14), ACT: 253.21 (+9.44), HHC: 142.99 (-0.69), PAH: 25.57 (+0.07), CP: 206.78 (+2.22), APD: 134.88 (+0.17), BKW: 32.30 (+0.01)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 135.35 (+1.14), ACT: 253.21 (+9.44), F: 15.44 (+0.30), FB: 75.32 (+0.44), PFE: 30.03 (-0.31), AGN: 213.00 (+14.35), YHOO: 51.44 (-0.31), PBR: 9.63 (-0.32), DFS: 64.80 (-0.18), DTSI: 32.96 (-0.07), SPY: 204.26 (+0.02), LNKD: 225.34 (-8.55), QQQ: 103.10 (-0.12), AME: 51.16 (-0.54), MRK: 59.86 (+0.79), AOL: 46.40 (+0.36), AZN: 71.97 (-0.88), GM: 32.10 (+0.31), CVEO: 10.62 (-0.02), DD: 70.65 (-0.15)
Actavis near deal to acquire Allergan for $210-220/share
Seeking Alpha - at Seeking Alpha - Sun Nov 16, 2:51PM CST
AGN: 213.00 (+14.35), ACT: 253.21 (+9.44), VRX: 135.35 (+1.14)
Eye Best Mutual Funds Like Magellan For Great Stocks
at Investor's Business Daily - Fri Nov 14, 4:50PM CST
Leery about picking stocks on your own? Novice traders with little knowledge or confidence to pick winning stocks may benefit by first seeing what great mutual funds are buying. Funds rule the market. After all, they spend millions, even billions, of...
KMX: 54.88 (-0.77), ACT: 253.21 (+9.44), APH: 50.74 (-0.12), JPM: 60.16 (-0.12), ALXN: 190.59 (+1.83), GOOGL: 548.25 (-6.94), BAC: 17.10 (-0.04), NXPI: 74.09 (+0.36), MSFT: 49.28 (-0.30), VZ: 51.31 (-0.19), AAPL: 114.75 (+0.57), UNP: 120.46 (-0.25)
Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.77 (+0.66), BIIB: 307.93 (+2.50), JNJ: 108.64 (+0.48), ACT: 253.21 (+9.44)
Valeant Should Drop Allergan Bid And Go For Zoetis
Kanak Kanti De - at Seeking Alpha - Fri Nov 14, 7:30AM CST
ZTS: 44.09 (+0.95), AGN: 213.00 (+14.35), VRX: 135.35 (+1.14), ACT: 253.21 (+9.44)
Will Actavis Snatch Allergan, Valeant Settle for Zoetis? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:28PM CST
A report from Bloomberg stated that Actavis is in discussions to Allergan for a deal worth at least $60 billion.
ZTS: 44.09 (+0.95), AGN: 213.00 (+14.35), ACT: 253.21 (+9.44), VRX: 135.35 (+1.14)
(0)
(0)Allergan plc (AGN) Stock Research Links
Scroll down for more posts ▼